

withdraw consent (n=9)  
 did not follow-up (n=3)  
 duodenal ulcer (n=14)  
 ulcer (n=12)

at least one dose of

PN200 ID 206	EC naproxen 500 mg BID n=203
(35)	60 (30)
(85)	173 (85)
(12)	20 (10)
(3)	10 (5)
1	61
(51)	100 (49)
(97)	201 (99)
(27)	52 (26)
(6)	4 (2)
(1)	0
(82)	169 (83)
(4)	14 (7)
0.5	0
(18)	25 (12)

back pain; chronic dental  
 chronic plantar fasciitis;  
 Dequervain's  
 arthritis; left Achilles  
 ; bilateral hand pain; pain





Figure 6. Survival analysis of incidence of duodenal ulcers over 6 months (ITT)



upper abdominal pain, dyspepsia, eructation, gastric discomfort

## Conclusions

- ▶ Compared with EC naproxen, PN200 was associated with a significantly lower incidence of both gastric ulcers and duodenal ulcers.
- ▶ Concomitant low-dose aspirin therapy had no significant effect on the observed gastric ulcer risk reduction seen with PN200.
- ▶ The PN formulation may offer a potential treatment option for patients at risk of NSAID-associated gastric ulcers or duodenal ulcers and may help address issues of persistence of use and compliance with gastroprotective agents.

## References

1. Lanas A et al. Am J Gastroenterol 2005; 100: 1685-1693.
2. Hawkey CJ et al. N Engl J Med 1998; 338: 727-734.
3. Scheiman JM. Curr Treat Options Gastroenterol 2008; 11: 125-134.
4. Goldstein JL et al. Clin Gastroenterol Hepatol 2006; 4: 1337-1345.
5. Sturkenboom MC et al. Aliment Pharmacol Ther 2003; 18: 1137-1147.

## Acknowledgements

Study PN200-301 was funded by POZEN Inc.

Editorial support was provided by Complete Medical Communications and was funded by AstraZeneca.

EULAR 2008, Paris, France, 11-14 June 2008

**DRL EXHIBIT 1012 PAGE 1**